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REGULAR ARTICLE
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Key Points
• The preferred donor for
patients with poor-risk
AML in CR1 pro-
ceeding to alloHSCT
include MRD or 10/10
MUD.
• Alternative donors are
9/10 MUD, UCB grafts,
and especially haplo,
but sufficient numbers
and follow-up to define
a hierarchy are lacking.
Allogeneic hematopoietic stem cell transplantation (alloHSCT) remains the treatment of
choice to consolidate remission in patients with poor-risk acute myeloid leukemia (AML).
With increasing alternative donors available, the preferred donor or stem cell source is
debated. We set out to study outcome in recipients of alloHSCT with poor-risk AML in ﬁrst
complete remission (CR1) by donor type. A total of 6545 adult patients with poor-risk AML in
CR1 receiving an alloHSCT using matched related donor (MRD, n 5 3511) or alternative
donors, including 10/10 (n 5 1959) or 9/10 matched unrelated donors (MUDs, n 5 549),
umbilical cord blood (UCB) grafts (n5 333), or haplo-identical (haplo) donors (n5 193) were
compared. Overall survival (OS) at 2 years following MRD alloHSCT was an estimated
596 1%, which did not differ from 10/10 MUD (57 6 1%) and haplo alloHSCT (57 6 4%). OS,
however, was signiﬁcantly lower for 9/10MUD alloHSCT (496 2%) and UCB grafts (446 3%),
respectively (P , .001). Nonrelapse mortality (NRM) depended on donor type and was
estimated at 266 3% and 296 3% after haplo alloHSCT and UCB grafts at 2 years vs 156 1%
followingMRD alloHSCT. Multivariable analysis conﬁrmed the impact of donor type with OS
followingMRD, 10/10 MUD, and haplo alloHSCT not being statistically signiﬁcantly different.
NRM was signiﬁcantly higher for alternative donors as compared with MRD alloHSCT.
Collectively, these results suggest that alloHSCT with MRDs and 10/10 MUDs may still be
preferred in patients with poor-risk AML in CR1. If an MRD or 10/10 MUD is not available,
then the repertoire of alternative donors includes 9/10 MUD, UCB grafts, and haplo-identical
donors. The latter type of donor is increasingly applied and now approximates results with
matched donors.
Submitted 21 October 2016; accepted 20 January 2017. DOI 10.1182/
bloodadvances.2016002386.
*J.J.C. and A.N. contributed equally to this study.
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Introduction
Allogeneic hematopoietic stem cell transplantation (alloHSCT) is
the most effective postremission treatment for prevention of
relapse in poor-risk acute myeloid leukemia (AML) in first complete
remission (CR1).1,2 Although most patients lack an HLA-matched
related donor (MRD), an alternative donor is available for almost
every patient in need of an alloHSCT.3 Although the probability
of identifying an adult matched unrelated donor (MUD) can be as
high as 60% to 80% for Caucasian patients, finding a suitable
MUD for patients from ethnic minorities is less successful.4-6 One
allele mismatched unrelated donor (MMUD) may serve as a good
alternative, but outcome has been associated with approximately
10% loss in overall survival (OS), which has predominantly been
ascribed to increased nonrelapse mortality (NRM).7 Following
the favorable results in pediatric patients, alloHSCT with umbilical
cord blood (UCB) grafts was also developed in adult patients.
Results of UCB alloHSCT in retrospective registry studies ap-
proximated those of MUD alloHSCT, although hematopoietic
recovery is delayed compared with MUD alloHSCT, and graft
failure was more frequently observed.8-10 More recently, a revived
interest in the use of haplo-identical (haplo) donors has become
apparent because of improved transplantation techniques and
pharmacological manipulation of host-versus-graft and graft-
versus-host reactions.11 Although each type of donor and/or stem
cell source has its own advantages and drawbacks, comparative
studies evaluating survival estimates in well-defined groups of
patients are scarce. Here, we set out to compare outcome in
patients with poor-risk AML in CR1 receiving alloHSCT between
2000 and 2014, using either MRD, 10/10 or 9/10 MUDs, haplo, or
UCB grafts.
Methods
Patients
A total of 6545 adult patients with poor-risk AML in CR1 receiving an
alloHSCT between 2000 and 2014 and reported to the European
Society for Blood and Marrow Transplantation (EBMT) Acute Leukemia
Working Party and Eurocord were eligible for the analysis. Patients were
transplanted with an MRD (n 5 3511) or alternative donors, including
10/10 (n 5 1959) or 9/10 MUDs (n 5 549), UCB grafts (n 5 333), or
haplo (n 5 193). Poor-risk AML was defined as described previously,12
with either white blood cell count (WBC) .100 3 109/L at diagnosis,
secondary AML, cytogenetic abnormalities associated with adverse
risk according to European LeukemiaNET classification,13 presence of
an fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD), or
no CR after 1 cycle of induction chemotherapy. Patients received
conditioning therapy followed by infusion of donor cells with either MRD
or alternative donors. In vivo T-cell depletion was defined as the use of
either antithymocyte globulin (ATG) or alemtuzumab. No ex vivo T-cell
depletion was performed on any of the patient grafts. The degree of HLA
matching was 9 or 10 of a 10 allele match for the MUDs, with mismatches
allowed at HLA-A, HLA-B, HLA-C, HLA-DR, or HLA-DQ levels for the
9/10 MUDs (supplemental Table 1). AlloHSCT with UCB grafts was
performed with either single or double cords. HLA matching for UCB was
done according to the standard criteria on antigen level for A and B and
allele level for DRB1. Haplo was defined as a $4/8 HLA match.
This study was a retrospective multicenter analysis and was performed in
accordance with the principles of the Declaration of Helsinki and approved
by the Acute Leukemia Working Party of the EBMT group. The EBMT is a
nonprofit, scientific society representing more than 600 transplant
centers, mainly in Europe. The EBMT promotes all activity aiming to
improve stem cell transplantation or cellular therapy, which includes
registering all the activity relating to stem cell transplants. Data are
entered, managed, and maintained in a central database with Internet
access; each EBMT center is represented in this database. There are no
restrictions on centers for reporting data, except for those required by the
law on patient consent, data confidentiality, and accuracy. Quality control
measures included several independent systems: confirmation of validity
of the entered data by the reporting team, selective comparison of the
survey data with minimum essential data A data sets in the EBMT registry
database, cross-checking with the national registries, and regular in-house
and external data audits. Since 1990, patients have provided informed
consent authorizing the use of their personal information for research
purposes.
End points
The primary end point of the study was OS at 2 years. Secondary end points
included relapse-free survival (RFS), relapse, NRM, and acute and chronic
graft-versus-host disease (GVHD) at 2 years. All outcome parameters were
measured from the date of transplantation. The event for OS was death,
whatever the cause, and patients were censored at the date of last contact if
alive. The events for RFS were death in CR1, designated as NRM, or
hematological relapse of the leukemia. Cumulative incidences of chronic
GVHD were estimated in patients without graft failure with death without
chronic GVHD as competing risk.
Statistical methods
Patient, disease, and transplant characteristics were compared by using the
x2 test for categorical variables and the Kruskal-Wallis test for continuous
variables. Probabilities of OS and RFS were calculated using the Kaplan-
Meier estimate.14 Cumulative incidence curves were used to estimate NRM
and relapse because NRM and relapse were competing events.15 Outcome
estimates are at 2 years unless explicitly stated otherwise. Multivariable Cox
regression analysis for OS, RFS, relapse, and NRM was applied with
adjustment for covariates, which were selected based on a P value,.05 by
univariate analysis. All analyses were done with Stata Statistical Software,
release 13.1 (Stata Corporation; 2013, College Station, TX).
Results
Patient characteristics
A total of 6545 patients with poor-risk AML in CR1 were included.
Patients received an alloHSCT from either an MRD (n 5 3511),
10/10 MUD (n5 1959), 9/10 MUD (n5 549), UCB graft (n5 333),
or haplo (n 5 193). Patient characteristics are shown in Table 1,
including the different poor-risk features of the AML, which were
differentially distributed among the donor types. Recipients of UCB
grafts were significantly younger compared with the other donor
types (median, 48 vs 52 years; P , .001). Poor-risk cytogenetics
and a FLT3-ITD were more frequently present in recipients of UCB
grafts and haplo alloHSCT (P 5 .016 and P , .001). The median
time from diagnosis to alloHSCT was 4.7 months, which was
significantly shorter for recipients of an MRD compared with the
alternative donors (median, 5.8 months; P , .001). In addition,
alternative donor transplantation has been performed more
frequently in recent years as compared with MRD alloHSCT
(P , .001). The median follow-up of patients still alive differed
between the patient groups, with a follow-up time of 43months (range,
1-188) for recipients of MRD alloHSCT, whereas follow-up
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was shorter for 10/10 MUD (24 months; range, 1-159), 9/10 MUD
(26 months; range, 1-139), UCB (24 months; range, 2-124), and
haplo (22 months; range, 1-120).
Transplant characteristics
Myeloablative conditioning (MAC) was applied in a higher pro-
portion in recipients of haplo (54%) andMRD (56%) compared with
patients receiving MUD (46%) or UCB grafts (45%) (Table 2). The
vast majority of MRD and MUD received peripheral blood stem cells,
whereas 52% of the haplo recipients received bone marrow cells.
Both family donors had a cytomegalovirus (CMV) donor match in
more than two-thirds of the transplants, whereas a CMV mismatch
was present in MUDs and UCB grafts in about 40% of the
transplants. Conditioning with total body irradiation was performed
mostly in recipients of UCB grafts (69%), particularly in patients
who received a UCB graft following reduced intensity conditioning
(RIC) (80%). In vivo T-cell depletion with either ATG or alemtuzumab
was used in the majority of MUDs (75%). In the haplo group,
90 (47%) haplo recipients received posttransplant cyclophos-
phamide without ATG, whereas 62 (32%) patients received an
ATG-based regimen as GVHD prophylaxis. Fourteen (7%) patients
received both ATG and posttransplant cyclophosphamide following
a haplo donor.
Transplant outcome
The rate of graft failure at 100 days after transplant was significantly
higher in recipients of UCB grafts and haplo compared with MRD
and 10/10 MUD alloHSCT (9% and 6% vs 2% and 1%, P , .001,
respectively; Table 3). Maximum grade of acute GVHD was slightly
increased in recipients of 9/10 MUDs and UCB grafts (P , .001;
Table 3; supplemental Table 2). Limited chronic GVHD was less
frequently present in recipients of UCB grafts, and the highest
incidence of chronic extensive GVHD was observed in MRD
Table 1. Patient characteristics
Donor source
MRD
(N 5 3511)
MUD 10/10
(N 5 1959)
MUD 9/10
(N 5 549)
UCB
(N 5 333)
Haplo
(N 5 193)
Sex P 5 .019
Male 1809 52% 1034 53% 275 50% 146 44% 110 57%
Female 1701 48% 925 47% 273 50% 187 56% 83 43%
Age, y P , .001
Median 50 54 52 48 51
Range 18-74 18-80 18-74 18-72 18-75
WBC at diagnosis P 5 .009
.100 1716 49% 897 46% 264 48% 177 53% 69 36%
#100 435 12% 176 9% 47 9% 36 11% 8 4%
Missing 1360 39% 886 45% 238 43% 120 36% 116 60%
Secondary AML P , .001
No 2207 63% 1068 55% 318 58% 208 62% 116 60%
Yes 1304 37% 891 45% 231 42% 125 38% 77 40%
Poor-risk cytogenetics (27/25/complex/11q23) P 5 .016
No 2028 58% 1109 57% 300 55% 163 49% 101 52%
Yes 1483 42% 850 43% 249 45% 170 51% 92 48%
FLT3-ITD P , .001
No 366 10% 271 14% 83 15% 53 16% 50 26%
Yes 605 17% 353 18% 101 18% 72 22% 42 22%
Missing 2540 72% 1335 68% 365 66% 208 62% 101 52%
CR reached after P , .001
Cycle 1 (early CR) 2536 72% 1529 78% 404 74% 253 76% 144 75%
Cycle 2 (late CR) 975 28% 430 22% 145 26% 80 24% 49 25%
Time from diagnosis to PRT, mo P , .001
Median 4.7 5.6 6.1 5.9 6.2
IQR 3.7-6.1 4.3-7.2 4.7-8.1 4.8-7.8 4.5-8.7
Year of PRT P , .001
Median 2008 2011 2011 2010 2012
Range 2000-2014 2000-2014 2000-2014 2000-2014 2000-2014
IQR, interquartile range; PRT, postremission treatment.
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recipients (Table 3). The cumulative incidence of chronic GVHD by
MRD, 10/10 MUD, 9/10 MUD, UCB, and haplo at 2 years is an
estimated 38 6 1%, 36 6 1%, 33 6 2%, 24 6 2%, and 37 6 4%,
respectively. With a median follow-up of 32 months, OS at 2 years
was not significantly different between MRD alloHSCT, 10/10 MUD
alloHSCT, and haplo alloHSCT (596 1%, 576 1%, and 576 4%,
respectively, P 5 .19; Figure 1A). However, OS was significantly
lower in recipients of 9/10 MUD alloHSCT and UCB grafts
compared with MRD alloHSCT (496 2%, 446 3%, and 596 1%,
respectively, P , .001; Figure 1A). These results were similar in
subgroups of poor-risk cytogenetics and secondary AML (supple-
mental Figure 1). RFS was 53 6 1%, 53 6 1%, and 52 6 4% at
2 years following MRD, 10/10 MUD, and haplo alloHSCT,
respectively, which was significantly (P , .001) better than following
UCB grafts (41 6 3%) or 9/10 MUD alloHSCT (44 6 2%)
(Figure 1B). The cumulative incidence of relapse at 2 years is an
estimated 22 6 3% for haplo alloHSCT, whereas other types
of donor transplantation were associated with a relapse incidence
of about 30% (Figure 1C). NRM depended on donor type and is
an estimated 266 3% and 296 3% after haplo and UCB alloHSCT
at 2 years, respectively, vs 15 6 1% following MRD alloHSCT
(Figure 1D). Causes of death by donor type are shown in
supplemental Table 3. Infections and GVHD were the most common
causes of nonrelapse death, which were increased in the alternative
donor transplants.
Multivariable analysis
The multivariable analysis is shown in Table 4 and was performed
with adjustment for donor type, age, cytogenetics, secondary AML,
time interval from diagnosis to transplant, year of transplant, in vivo
T-cell depletion, and conditioning type. OS was not significantly
different comparing alloHSCT following MRD with 10/10 MUD, and
haplo alloHSCT (hazard ratio [HR], 0.99 and 1.12, respectively).
OS following both 9/10 MUD and UCB grafts was significantly
worse compared with MRD (HR, 1.23; P 5 .005; and HR, 1.54;
P , .001, respectively). A similar pattern was found for RFS with
nonsignificant differences for MRD, 10/10 MUD, and haplo
alloHSCT, whereas both 9/10 MUD alloHSCT and UCB grafts
were associated with worse RFS. Relapse was decreased for
10/10 MUD (HR, 0.74; P , .001) and haplo (HR, 0.60; P 5 .001)
compared with MRD alloHSCT. NRM was significantly higher for all
alternative donors compared with MRD alloHSCT. Older age was
associated with increased risk for all outcome parameters. Both
poor-risk cytogenetics and secondary AML had an increased HR for
OS, RFS, and relapse, whereas a shorter time from diagnosis to
transplant predicted for better OS, RFS, and relapse. A higher
Table 2. Transplant characteristics
Donor source
MRD
(N 5 3511)
MUD 10/10
(N 5 1959)
MUD 9/10
(N 5 549)
UCB
(N 5 333)
Haplo
(N 5 193)
Conditioning P , .001
MAC 1951 56% 888 45% 256 47% 145 44% 104 54%
RIC 1518 43% 1056 54% 291 53% 183 55% 89 46%
Missing 42 1% 15 1% 2 0% 5 2% 0
Peripheral stem cells P , .001
No 712 20% 315 16% 76 14% 333 100% 100 52%
Yes 2799 80% 1644 84% 473 86% 0 93 48%
CMV patient/donor P , .001
neg/neg 717 20% 585 30% 129 23% 64 19% 32 17%
pos/neg 522 15% 582 30% 166 30% 93 28% 35 18%
neg/pos 324 9% 166 8% 74 13% 42 13% 12 6%
pos/pos 1587 45% 582 30% 166 30% 78 23% 111 58%
Missing 361 10% 44 2% 14 3% 56 17% 3 2%
TBI given P , .001
No 2480 71% 1422 73% 424 77% 130 39% 141 73%
Yes 1028 29% 535 27% 124 23% 203 69% 52 27%
Female donor to male recipient P , .001
No 2710 77% 1739 89% 472 86% 273 82% 147 76%
Yes 801 23% 220 11% 77 14% 60 18% 46 24%
In vivo T-cell depletion P , .001
No 2354 67% 535 27% 73 13% 198 59% 111 58%
ATG 707 20% 1201 61% 393 72% 123 37% 78 40%
Alemtuzumab 237 7% 216 11% 80 15% 0 3 2%
Missing 213 6% 7 0% 3 1% 12 4% 1 1%
TBI, total body irradiation.
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HR for relapse was found for RIC compared with MAC (HR, 1.23;
P, .001), which was counterbalanced by a lower HR for NRM (0.78,
P, .001), resulting in similar OS and RFS comparing RIC and MAC.
A detailed analysis of the different alternative donors following either
a RIC or MAC preparative regimen is presented in supplemental
Table 4. Higher NRM associated with 9/10 MUD, UCB, and
following haplo donors was observed after both RIC and MAC, but
appeared most pronounced after MAC. OS again showed similar
survival following MRD and 10/10 MUD.
Discussion
Postremission therapy by alloHSCT remains the treatment of
choice in poor-risk AML patients upon achieving CR1 and qualifying
for intensive therapy.1,2 Possible donor sources currently include
MRDs or alternative donors such as MUDs with either a 10/10 or
9/10 HLA match, UCB grafts, or haplo. The present retrospec-
tive study from the EBMT Acute Leukemia Working Party demon-
strates similar OS for patients with poor-risk AML in CR1 following
alloHSCT with either MRD or 10/10 MUD. In contrast, recipients of 9/
10 MUD and UCB grafts experienced worse outcome compared with
MRD or 10/10 MUD, which was mainly the result of increased NRM.
Recipients of T-cell replete haplo alloHSCT showed encouraging
outcomes, which appeared not statistically different from MRD and 10/
10 MUD, although a larger cohort and longer follow-up may be needed.
Historically, alloHSCT with an MRD has been the preferred type of
donor for patients with hematological diseases. However, 70% of
the patients lack a suitable MRD and the use of older MRD in elderly
AML patients has recently been questioned.16,17 The present study
confirms that an MRD should still be considered the preferred
donor. AlloHSCT with a 10/10 MUD yielded similar survival in the
present study, confirming 10/10 MUD as the preferred alternative if
an MRD is not available. Several study groups have compared
outcome of transplantation using either MRD or MUD in patients
with AML and reported similar survival rates.18-22 Some studies
reported slightly higher NRM following MUD, whereas counter-
balancing lower relapse resulted in similar outcome compared with
MRD, which was also found in the present study.
Inferior survival was found for recipients of MMUDs (9/10 HLA
match) compared with MRD, which was primarily caused by
increased incidence of (severe) GVHD and subsequent NRM.
A recent meta-analysis of 7 retrospective studies comparing 10/10
MUD and 9/10 MUD alloHSCT showed a 27% increased risk of
mortality for recipients of a 9/10 MUD.23 Here, a similarly increased
risk (25%) was found when comparing 9/10 MUDs with 10/10
MUDs in patients with poor-risk AML in CR1. These results suggest
that transplants using 9/10 MUDmay be followed by more stringent
prevention of GVHD to limit NRM. Studies addressing the value of
intensified GVHD prophylaxis, such as being applied in a haplo
Table 3. Transplant outcome
Donor source
MRD
(N 5 3511
MUD 10/10
(N 5 1959)
MUD 9/10
(N 5 549)
UCB
(N 5 333)
Haplo
(N 5 193)
Graft failure P , .001
No. of patients 53 2% 29 1% 20 4% 30 9% 11 6%
Time to engraftment, d P , .001
Median 16 17 17 23 18
IQ range 13-20 14-20 14-20 17-30 15-23
Acute GVHD (maximum grade) P , .001
Grade 0-1 2623 75% 1369 70% 374 68% 220 66% 140 73%
Grade 2-4 769 22% 518 26% 156 28% 99 30% 49 25%
Unknown 119 3% 72 4% 19 3% 14 4% 4 2%
Time transplant to acute GVHD, d P , .11
Median 28 27 25 28 29
IQR 18-47 17-43 16-42 19-38 18-48
Chronic GVHD P , .001
Mild 533 15% 283 14% 81 15% 28 8% 39 20%
Extensive 712 20% 310 16% 73 13% 37 11% 18 9%
Time transplant to chronic GVHD, mo P , .001
Median 6.0 5.4 5.6 4.9 6.4
IQ range 4.0-9.6 3.7-8.3 3.7-8.3 4.1-6.9 4.1-9.6
Outcome at 2 y
OS 59 6 1% 57 6 1% 49 6 2% 44 6 3% 57 6 4%
RFS 53 6 1% 53 6 1% 44 6 2% 41 6 3% 52 6 4%
Relapse 32 6 1% 27 6 1% 31 6 2% 30 6 3% 22 6 3%
NRM 15 6 1% 20 6 1% 24 6 2% 29 6 3% 26 6 3%
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alloHSCT setting, may possibly direct how to improve transplants
with MMUDs.11,24
Following the initial favorable results in pediatric patients, alloHSCT
with UCB grafts was also developed in adults with acute leukemia. Al-
though a higher incidence of graft failure and delayed hematopoietic
recovery are associated with UCB grafts, largely similar outcomes
comparedwithMRD,MUD, orMMUDalloHSCTwere reported.9,10,25,26
However, these studies included different groups of patients, which
hampered a precise comparison. The present study in a homogenous
group of patients shows that alloHSCT with UCB grafts is still
associated with higher NRM compared with MRD, which resulted in
significantly lower OS. The incidence of graft failure following alloHSCT
with UCB grafts in our study is an estimated 9% and the majority of
causes of death were infections, to which graft failure and delayed
recovery contributed. No significant differences in outcome were found
between single vs double UCB grafts, and no difference between UCB
with low vs high total nucleated cells at infusion of the UCB grafts were
found, although information was not available for all UCB grafts (data not
shown). These results suggest that improving hematopoietic engraft-
ment and hematopoietic recovery remains a major challenge in UCB
graft alloHSCT in adult patients, which is currently addressed and
studied by several groups exploring expansion of UCB hematopoi-
etic stem cells.27,28
Allogeneic transplantation with a haplo-identical family donor was
extensively studied by the Perugia group.29 Although that approach
consisting of transplantation with high numbers of CD341 cells,
intensified conditioning and stringent GVHD prophylaxis appeared to
result in favorable engraftment in the majority of patients, a relatively
high NRM precluded application on a broader scale. More recently,
both the approach by the Baltimore group based on posttransplant
cyclophosphamide and the Chinese approach based on in vivo T-cell
depletion were demonstrated to result in favorable engraftment, limited
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Figure 1. Outcome by different donor types. Kaplan-Meier estimates of OS (A), RFS (B), relapse (C), and NRM (D) by donor type of patients with poor-risk AML in CR1.
F, number of failures (ie, death whatever the cause); Cox LR, Cox likelihood ratio.
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GVHD, and limited NRM.30,31 A recent biologically randomized study
from China suggested similar outcomes using matched related or
haplo-identical family donors.30 Updated results from the Baltimore
group also suggested similar survival following haplo alloHSCT and
matched donor alloHSCT.31 A recent retrospective study from the
Acute Leukemia Working Party of the EBMT showed a similar relapse
incidence in patients receiving T cell–replete and T cell–depleted haplo
alloHSCT compared with MRD, which suggested a similar graft-
versus-leukemia effect.32 The present study included T cell–replete
haplo alloHSCT, which appeared associated with a stronger graft-
versus-leukemia effect compared with MRD (HR, 0.60), whereas
severe grades of acute and chronic GVHD were relatively low
comparedwith the other donor types. A large retrospective study of the
Center for International Blood and Marrow Transplant Research
comparing MRD with haplo alloHSCT using posttransplant cyclo-
phosphamide also found less GVHD following haplo alloHSCT and an
overall similar outcome.33 Our study showed a relatively low incidence
of relapse following haplo alloHSCT, but a higher incidence of NRM,
resulting in a similar outcome compared with MRD alloHSCT. Both the
relatively short follow-up and unknown patient selection preclude more
definite conclusions as regards the comparison with sibling donors.
However, haplo alloHSCT was also suggested to result in better
outcome compared with UCB alloHSCT. In a less homogenous group
of AML patients, UCB and haplo alloHSCT were previously suggested
to result in similar overall outcome.34 The latter results are in line with
the 2 parallel phase 2 trials of Brunstein et al, which addressed UCB
grafts and unmanipulated haplo alloHSCT including posttransplant
cyclophosphamide. Although haplo was associated with less NRM,
a higher relapse rate counterbalanced that favorable effect, resulting
in similar RFS. Currently, a prospective randomized phase 3 trial is being
conducted comparing UCB and haplo alloHSCT (BMT CTN 1101),
which will address the question how UCB and haplo alloHSCT compare
in patients with hematological malignancies.
Our study may have several limitations. First, a center’s preference
regarding preferred alternative donors may result in selection bias.35
Reasons for the choice of an alternative donor transplant are not
registered in the EBMT database and therefore not known. We
focused on a homogenous group of poor-risk AML patients with no
important differences in baseline characteristics, but time intervals
from diagnosis to transplant did differ, which may be associated
with selection resulting from exclusion of early relapses in the group of
alloHSCT recipients with the longest timeframe. Second, an in-
creasingly important parameter is the presence or absence of minimal
residual disease, which was unknown in the present study, but has
recently been shown to strongly predict for subsequent relapse and
overall outcome.36-39 Although not recorded, residual disease is not
routinely assessed in most centers and also not uniformly used for
risk-adapted treatment; as a result, it is unlikely to have resulted in a
strong selection bias. Last, the retrospective multicenter nature of our
study implies that the physician/centers intention and/or preference is
not taken into account, which can only be addressed in a prospective
randomized study. However, prospective studies with more than 2
or 3 donor types will be extremely difficult, necessitating larger reg-
istry studies. To our knowledge, our study is the largest compara-
tive study of MRD and alternative donors in the homogenous
subgroup of patients with poor-risk ALM in CR1 in urgent need of
an alloHSCT. Our results compare well with a recent study by
Raiola et al, who performed a single-center retrospective study of
459 patients that received alloHSCT using different donors, including
unmanipulated haplo, MRD, MUD, or UCB grafts. Although the
recipients suffered from various hematological malignancies and
haplo has been performed more frequently in recent years, their
results also suggested higher NRM in MMUD alloHSCT and fol-
lowing alloHSCT with UCB grafts.40
In conclusion, our study suggests that well-matched donors
including MRD and 10/10 MUD are preferred over UCB and
Table 4. Multivariable analysis
OS RFS Relapse NRM
HR* 95% CI P value HR* 95% CI P value HR* 95% CI P value HR* 95% CI P value
Donor source
MUD 10/10 vs MRD 0.99 0.90-1.09 .89 0.93 0.85-1.02 .11 0.74 0.66-0.83 ,.001 1.39 1.19-1.62 ,.001
MUD 9/10 vs MRD 1.23 1.07-1.42 .005 1.17 1.02-1.34 .023 0.93 0.78-1.11 .44 1.77 1.43-2.20 ,.001
UCB vs MRD 1.54 1.31-1.81 ,.001 1.37 1.17-1.60 ,.001 0.96 0.77-1.19 .69 2.41 1.92-3.04 ,.001
Haplo vs MRD 1.12 0.89-1.40 .34 1.00 0.81-1.25 .97 0.60 0.44-0.84 .001 1.98 1.47-2.68 ,.001
Age† 1.17 1.13-1.21 ,.001 1.13 1.09-1.16 ,.001 1.07 1.02-1.12 .002 1.22 1.16-1.29 ,.001
Poor-risk cytogenetics (yes vs no) 1.31 1.20-1.44 ,.001 1.36 1.25-1.48 ,.001 1.66 1.49-1.85 ,.001 0.95 0.82-1.09 .47
Secondary AML (yes vs no) 1.35 1.23-1.48 ,.001 1.33 1.22-1.46 ,.001 1.28 1.14-1.44 ,.001 1.40 1.21-1.61 ,.001
Time from diagnosis to transplant‡ 0.99 0.98-1.00 .095 0.99 0.98-1.00 .039 0.97 0.96-0.99 .002 1.00 0.99-1.02 .69
Year of transplant§ 0.96 0.85-1.09 .50 0.95 0.84-1.06 .36 1.03 0.89-1.19 .68 0.80 0.66-0.98 .029
Conditioning (RIC vs MAC) 0.98 0.90-1.06 .59 1.03 0.95-1.12 .42 1.23 1.11-1.37 ,.001 0.78 0.68-0.89 ,.001
In vivo T-cell depletion (yes vs no) 1.04 0.95-1.13 .37 1.06 0.98-1.15 .15 1.13 1.02-1.25 .023 0.94 0.82-1.07 .35
CI, confidence interval; NRM, time as RFS with event death in first CR and censored at relapse; relapse, time as RFS and with event relapse and censored at death in first CR.
*The HRs are the estimates of the effect of covariates for each outcome parameter, adjusted for donor, age, poor-risk cytogenetics, secondary AML, time from diagnosis to transplant, year of
transplant, conditioning type, and in vivo T-cell depletion.
†Linear with estimates of 10-y difference.
‡Linear with estimates of 1-mo difference.
§Linear with estimates of 10-y difference.
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MMUD patients with poor-risk AML in CR1. Nine of 10 MUD, UCB
grafts, and haplo-identical donors could be used as alternatives in
case a fully matched donor is not available or an urgent transplant
is required. Haplo-identical donors are increasingly used, and
results are encouraging. However, comparative prospective studies
of haplo alloHSCT with other donor types are warranted and longer
follow-up after haplo alloHSCT may be needed to definitely establish
its place in the hierarchy of alternative donors.
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